Australia Aims To Drive Etanercept Uptake By Broadening Brenzys Listing
Australian authorities are looking to drive uptake of biosimilar etanercept by broadening a reimbursement listing for MSD’s Brenzys, while an advisory committee continues to ponder listings for trastuzumab biosimilars.
You may also be interested in...
Celltrion Healthcare’s Truxima has become the second rituximab biosimilar to be listed on Australia’s Pharmaceutical Benefits Schedule. But unlike Sandoz’ Riximyo version, Truxima is only eligible for oncology indications under a chemotherapy funding scheme.
Australia’s Juno Pharmaceuticals has struck a deal with Korea’s Celltrion to partner on marketing biosimilar trastuzumab and rituximab.
A body that advises Australia’s Department of Health on reimbursement will in November consider listing applications for Sandoz’ Ziextenzo pegfilgrastim candidate and well as for Pfizer’s recently authorized Trazimera trastuzumab brand.